AR003112A1 - Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas - Google Patents

Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas

Info

Publication number
AR003112A1
AR003112A1 ARP960101759A AR10175996A AR003112A1 AR 003112 A1 AR003112 A1 AR 003112A1 AR P960101759 A ARP960101759 A AR P960101759A AR 10175996 A AR10175996 A AR 10175996A AR 003112 A1 AR003112 A1 AR 003112A1
Authority
AR
Argentina
Prior art keywords
expression
gene
dna
cell
structural gene
Prior art date
Application number
ARP960101759A
Other languages
English (en)
Original Assignee
Docampo Palacios Maite L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Docampo Palacios Maite L filed Critical Docampo Palacios Maite L
Publication of AR003112A1 publication Critical patent/AR003112A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un método para controlar la expresión de un gen estructural en una célula que comprende las etapas de:a) proporcionar una construcción de ADNque comprende una secuencia de inserción dirigida, una secuencia reguladora y un sitiodonador de empalme;b)establecer una secuencia de ADN interventor entrela secuencia reguladora y el gen estructural por inserción de la construcción en la célula por recombinación homóloga en una posición preseleccionada conrespecto al genestructural para producir una célula homólogamente recombinante en que la construcción insertada adopta una configuración por la que lasecuencia reguladora se separa del gen estructural por una longitud preseleccionada de ADNinterventor,estando colocado el sitio donador de empalmede manera que se separa ARN cognaticio del ADN interventor durante el empalme post-transcripcional del transcripto primario; y c) controlar la expresión delgen estructural por variación de lalongitud de ADN interventor seleccionado en la etapa (b). Las construcciones de inserción dirigida comprenden al menos: a)una secuencia dirigida;b) una secuencia reguladora; c) un exón; y d) un sitio donador de empalme. Dichas construcciones quepueden experimentar recombinac iónhomóloga con secuencias celulares endógenas para generar un gen novedoso, se introducen en células para producir células homólogamente recombinantes. Lascélulas dan como resultado la producción de uno cualquierade trombopoyetina, ADNasa I o interferón Beta. La invención se refiere además a métodos deproducción de preparaciones farmacéuticamente útiles que contienen trombopoyetina, ADNasa (I) o inteferón Beta a partir de célulashomólogamenterecombinantes y métodos de terapi a.
ARP960101759A 1995-03-17 1996-03-15 Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas AR003112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/406,030 US6270989B1 (en) 1991-11-05 1995-03-17 Protein production and delivery

Publications (1)

Publication Number Publication Date
AR003112A1 true AR003112A1 (es) 1998-07-08

Family

ID=23606267

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101759A AR003112A1 (es) 1995-03-17 1996-03-15 Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas

Country Status (10)

Country Link
US (1) US6270989B1 (es)
EP (1) EP0815232A1 (es)
JP (1) JPH11502122A (es)
AR (1) AR003112A1 (es)
AU (1) AU725832B2 (es)
CA (1) CA2215618A1 (es)
IL (1) IL117468A0 (es)
MY (1) MY134810A (es)
WO (1) WO1996029411A1 (es)
ZA (1) ZA962116B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP1783139B8 (en) 1996-10-01 2009-09-23 Geron Corporation Human telomerase catalytic subunit
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
GB9715064D0 (en) * 1997-07-17 1997-09-24 Ppl Therapeutics Scotland Ltd Protein expression
TR200000172T2 (tr) * 1997-07-23 2000-12-21 Roche Diagnostics Gmbh Mutasyona uğramış insan proteinlerinin insan hücrelerinde homolog tekrar birleşim ile üretilmesi.
DK0986644T3 (da) * 1997-07-23 2007-01-29 Roche Diagnostics Gmbh Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
US6395484B1 (en) * 1997-07-23 2002-05-28 Roche Diagnostics Gmbh Identification of human cell lines for the production of human proteins by endogenous gene activation
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
PT1000154E (pt) 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
DE69841723D1 (de) * 1997-09-26 2010-07-29 Abt Holding Co Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US7316923B1 (en) * 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
CN1174993C (zh) 1997-11-03 2004-11-10 人体基因组科学有限公司 Vegi,一种血管发生和肿瘤生长的抑制剂
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
EP1115867A1 (en) 1998-09-21 2001-07-18 Schering Corporation Human interleukin-b50. therapeutic uses
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
CA2364267A1 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US20050129669A1 (en) * 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
JP2003506026A (ja) 1999-07-30 2003-02-18 シェーリング コーポレイション 哺乳動物サイトカイン；関連試薬
EP1905832A3 (en) 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
GB0018876D0 (en) 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20040219525A1 (en) 2000-08-25 2004-11-04 Heiko Haertel Plant polynucleotides encoding novel prenyl proteases
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP2327985B2 (en) 2001-06-26 2019-08-21 Senomyx, Inc. T1R Hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
AU2002318229B2 (en) 2001-07-10 2008-03-13 Senomyx, Inc. Use of specific T2R taste receptors to identify compounds that block bitter taste
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
JP2005516607A (ja) 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
EP1587545A2 (en) * 2003-01-13 2005-10-26 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8227212B2 (en) 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
US7205148B2 (en) * 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
BRPI0413324A (pt) 2003-08-06 2006-10-10 Senomyx Inc receptores de paladar hetero-oligoméricos t1r, linhas de células que expressam os ditos receptores, e compostos de paladar
EP2260776A1 (en) * 2003-11-21 2010-12-15 Vnus Medical Technologies, Inc. Apparatus for treating the carotid artery
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
ES2658859T3 (es) 2005-10-20 2018-03-12 Senomyx, Inc. Receptores del sabor dulce-umami y umami-dulce humanos quiméricos
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
WO2007124152A2 (en) 2006-04-21 2007-11-01 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
CA2982520A1 (en) 2007-08-21 2009-02-26 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
EP2279210B1 (en) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
EP2863941B1 (en) 2012-03-02 2018-12-19 Shire Human Genetic Therapies, Inc. Velaglucerase for treating type iii gaucher disease
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
JP7175608B2 (ja) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 加齢に伴うフレイルのための治療としてのオステオカルシン
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
MX2020001913A (es) * 2017-08-18 2020-09-07 Neutrolis Inc Enzimas dnasa modificadas y uso en terapia.
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
JP2022504400A (ja) 2018-10-08 2022-01-13 ニュートロリス インコーポレイテッド 製造及び治療のためのｄｎａｓｅ酵素の操作
PE20220604A1 (es) * 2019-09-20 2022-04-25 Ractigen Therapeutics Molecula de acido nucleico para el tratamiento de la trombocitopenia y uso de la misma

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
EP0038765B1 (fr) 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
US4751348A (en) * 1983-07-16 1988-06-14 Cold Spring Harbor Laboratory Nicotiana plants with both altered polyamine levels and flower structures and method for obtaining these plants
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
CA1215922A (en) 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
ES2094720T3 (es) 1987-05-01 1997-02-01 Gen Hospital Corp Implantacion transcariotica.
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5171674A (en) * 1988-07-13 1992-12-15 Brigham And Women's Hospital Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0747485B1 (en) 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
ES2151463T5 (es) 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
JPH04505710A (ja) 1990-02-22 1992-10-08 ファーミング　ビーブイ ポリペプチドの改良された発現
IT1241123B (it) 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP0535144A4 (en) 1990-06-12 1993-08-11 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
JPH06509474A (ja) * 1991-07-31 1994-10-27 ローヌ−プーラン・ローラー・インターナシヨナル（ホールデイングス）インコーポレイテツド 蛋白質のトランスジェニック生産
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU710255B2 (en) * 1991-11-05 1999-09-16 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
MX9305183A (es) 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
ATE155581T1 (de) 1992-11-02 1997-08-15 Genentech Inc Verdichtungsprüfung zur bewertung einer therapie für eine atmungskrankheit
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin

Also Published As

Publication number Publication date
AU725832B2 (en) 2000-10-19
MY134810A (en) 2007-12-31
IL117468A0 (en) 1996-07-23
EP0815232A1 (en) 1998-01-07
AU5362596A (en) 1996-10-08
WO1996029411A1 (en) 1996-09-26
CA2215618A1 (en) 1996-09-26
JPH11502122A (ja) 1999-02-23
ZA962116B (en) 1996-10-03
US6270989B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
AR003112A1 (es) Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas
US4332892A (en) Protein synthesis
Padgett et al. Splicing of messenger RNA precursors
AR005568A1 (es) Moleculas y construcciones de adn para aumentar la expresion de genes foraneos; celulas y plantas transformadas y metodo para producirlas
MX9605542A (es) Produccion de proteinas y liberacion de proteinas.
Hellerman et al. Secretion of human parathyroid hormone from rat pituitary cells infected with a recombinant retrovirus encoding preproparathyroid hormone.
US4418149A (en) Fused hybrid gene
HU195534B (en) Process for preparing polypeptide by bacterial way, by using tryptophan promoter operator
JP6284181B2 (ja) 環状ｒｎａ及びタンパク質の製造方法
DK0750044T3 (da) DNA-konstruktioner og transfektion af celler dermed til homolog rekombination
WO2002014495B1 (en) Enhanced homologous recombination mediated by lambda recombination proteins
EP1328653A4 (en) HIGHLY EXPRESSIBLE GENES
ES2195998T3 (es) Sistemas de expresion de dna basados en alfavirus.
WO2003008573A3 (en) Silencing of gene expression by sirna
CN112912497B (zh) 工程化长散在元件(line)转座子及其使用方法
US11939580B2 (en) Construct of self-circularization RNA
ES2116683T3 (es) Gen de la beta-galactosidasa hipertermoestable.
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
ATE246249T1 (de) Für ammonium-transporter kodierende dna-sequenzen und dieser enthaltende, plasmide, bakterien, hefen und pflanzenzellen
GR900100012A (el) Μέ?οδος εισαγωγής εξωγενούς DNA σε σωματικά και γεννητικά ζωικά κύτταρα.
DE59510829D1 (de) Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen
JP7416745B2 (ja) 改変細胞、調製方法、及び構築物
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
ES2061524T3 (es) Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona.
GB2039916A (en) Protein synthesis by genetic manipulation

Legal Events

Date Code Title Description
FB Suspension of granting procedure